A quercetin containing supplement reduces in niacin-induced flush in humans

International Journal of Immunopathology and Pharmacology

Volumn 21, Issue 3, 2008, Pages 509-514

  Kalogeromitros, D ^a   Makris, M ^a   Chliva, C ^a   Aggelides, X ^a   Kempuraj, D ^b   Theoharides, Theoharis C ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Flavonoids; Flush; Niacin; Prostaglandins; Quercetin; Serotonin; Skin

Indexed keywords

ALGONOT-PLUS; NICOTINIC ACID; PROSTAGLANDIN D; QUERCETIN; SEROTONIN; SLO NIACIN; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ARTICLE; BURNING SENSATION; CELL SECRETION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE DURATION; DRUG EFFICACY; EDEMA; FACE ERYTHEMA; FLUSHING; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; MAST CELL; NORMAL HUMAN; PILOT STUDY; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; PROSTAGLANDIN RELEASE; PRURITUS; RATING SCALE; SCORING SYSTEM; SEROTONIN BLOOD LEVEL; SIDE EFFECT; SKIN TEMPERATURE; SUSTAINED DRUG RELEASE; SYMPTOM; TREATMENT RESPONSE;

EID: 53749103108     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200802100304     Document Type: Article

References (35)

1. McCormack PL, Keating GM. Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. Drugs 2005; 65:2719-40.
2. Stern RH, Spence JD, Freeeman DJ, Parbtani A. Tolerance to nicotinic acid flushing. Clin Pharmacol Ther 1991; 50:60-70.
3. Karas RH, Kashyap ML, Knopp RH, Keller LH, Bajorunas DR, Davidson MH. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs 2008; 8: 69-81.
4. Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type Ila or type IIb hyperlipidemia. J Am Coll Cardiol 2008; 51: 1564-72.
5. Gupta EK, Ito MK. Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia. Heart Dis 2002; 4:124-37.
6. Knip M, Douek IF, Moore WP, Gillmor HA, McLean AE, Bingley PJ, Gale EA. Safety of high-dose nicotinamide: a review. Diabetologia 2000; 43:1337-45.
7. Meyers CD, Carr MC, Park S, Brunzell JD. Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia. Ann Intern Med 2003; 139:996-1002.
8. 2 in vivo in humans following administration of nicotinic acid. Prostaglandins 1989; 38:263-74.
9. Morrow JD, Awad JA, Oates JA, Roberts LJ. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol 1992; 98:812-5.
10. 2 synthetase in histiocytes, dendritic and Kupffer cells in various rat tissues. J Immunol 1989; 143:2982-7.
11. Jungnickel PW, Maloley PA, Vander Tuin EL, Peddicord TE, Campbell JR. Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. J Gen Intern Med 1997; 12:591-6.
12. Guyton JR, Bays HE. Safety consideration with niacin therapy. Am J Cardiol 2007; 99:22C-31C.
13. Turenne SD, Seeman M, Ross BM. An animal model of nicotinic-acid-induced vasodilation: effect of haloperidol, caffeine and nicotine upon nicotinic acid response. Schizophrenia Res 2001; 50:191-7.
14. Papaliodis D, Boucher W, Kempuraj D, Theroharides TC. The flavonoid luteolin inhibits niacin-induced flush. Br J Pharmacol 2008; 153:1382-7.
15. Kempuraj D, Saito H, Kaneko A, Fukagawa K, Nakayama M, Toru H, Tomikawa M, Tachimoto H, Ebisawa M, Akasawa A, Miyagi T, Kimura H, Nakajima T, Tsuji K, Nakahata T. Characterization of mast cell-committed progenitors present in human umbilical cord blood. Blood 1999; 93:3338-46.
16. Kempuraj D, Huang M, Kandere-Grzybowska K, Basu S, Boucher W, Letourneau R, Athanasiou A, Theoharides TC. Azelastine inhibits secretion of IL-6, TNF-α and IL-8 as well as NF-kB activation and intracellular calcium ion levels in normal human mast cells. Int Arch Allergy Immunol 2003; 132:231-9.
17. Middleton E Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer. Pharmacol Rev 2000; 52:673-751.
18. Kempuraj D, Madhappan B, Christodoulou S, Boucher W, Cao J, Papadopoulou N, Cetrulo CL, Theoharides TC. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. Br J Pharmacol 2005; 145:934-44.
19. Kimata M, Shichijo M, Miura T, Serizawa I, Inagaki N, Nagai H. Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. Clin Exp Allergy 2000; 30:501-8.
20. Hirano T, Higa S, Arimitsu J, Naka T, Shima Y, Ohshima S, Fujimoto M, Yamadori T, Kawase I, Tanaka T. Flavonoids such as luteotin, fisetin and apigenin are inhibitors of interleukin-4 and interleukin-13 production by activated human basophils. Int Arch Allergy Immunol 2004; 134:135-40.
21. Hu C, Kitts DD. Luteolin and luteolin-7-O-glucoside from dandelion flower suppress iNOS and COX-2 in RAW264.7 cells. Mol Cell Biochem 2004; 265:107-13.
22. Rivera L, Moron R, Sanchez M, Zarzuelo A, Galisteo M. Querectin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obesity (Silver, Spring) 2008; 16:2081-7.
23. 2 from mast cells and serotonin from platelets: Evidence from human cells in vitro and an animal model. J Pharmacol Exp Ther 2008, in press.
24. Gershon RK, Askenase PW, Gershon MD. Requirement for vasoactive amines for production of delayed-type hypersensitivity skin reactions. J Exp Med 1975; 142:732-47.
25. Matuchansky C, Laimay JM. Serotonin, catecholamines, and spontaneous midgut carcinoid flush: plasma studies from flushing and nonflushing sites. Gastroenterology 1995; 108:743-51.
26. Boushey RP, Dackiw AP. Carcinoid tumors. Curr Treat Options Oncol 2002; 3:319-26.
27. Wink J, Giacoppe G, King J. Effect of very-low-dose niacin on high-density lipoprotein in patients undergoing long-term statin therapy. Am Heart J 2002; 143:514-8.
28. Morgan JM, Capuzzi DM, Guyton JR, Centor RM, Goldberg R, Robbins DC, DiPette D, Jenkins S, Marcovina S. Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: A placebo-controlled trial. J Cardiovasc Pharmacol Ther 1996; 1:195-202.
29. Morgan JM, Capuzzi DM, Guyton JR. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol 1998; 82:29U-34U.
30. Miller M. Niacin as a component of combination therapy for dyslipidemia. Mayo Clin Proc 2003; 78: 735-42.
31. Meyers CD, Kamanna VS, Kashyap ML. Niacin therapy in atherosclerosis. Curr Opin Lipidol 2004; 15:659-65.
32. Guyton JR, Goldberg AC, Kreisberg RA, Sprecher DL, Superko HR, O'Connor CM. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998; 82:737-43.
33. Carlson LA. Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug. Int J Clin Pract 2004; 58:706-13.
34. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 2004; 164:697-705.
35. Whelan AM, Price SO, Fowler SF, Hainer BL. The effect of aspirin on niacin-induced cutaneous reactions. J Fam Pract 2005; 34:165-8.